Chapter 14 of 25
What you will learn
- Understand the usual eligibility criteria.
- Separate temporary cancer control from a guarantee of pregnancy.
- Recognize the importance of response biopsies and stopping rules.
Who may qualify?
The usual candidate has grade-1 endometrioid carcinoma, no myometrial invasion and no evidence of disease outside the uterus. Expert pathology confirmation and pelvic MRI or expert ultrasound are important. The team also considers genetic risk, ovarian findings, other illnesses and the ability to attend close follow-up.
Higher-grade disease, aggressive histology, muscle invasion or extrauterine spread generally makes routine conservative treatment inappropriate. Exceptional approaches should be discussed only within highly specialized care or research. A reassuring molecular result does not automatically make an otherwise unsafe fertility-preserving plan acceptable.
Treatment options
Progestin therapy can be delivered orally, through a levonorgestrel intrauterine system, or in combination. Selected specialist pathways include hysteroscopic removal of visible disease followed by progestin treatment. This differs from endometrial ablation, which is not an appropriate cancer treatment. Medicine choice and dose require specialist prescribing and monitoring.
Possible adverse effects include irregular bleeding, appetite or weight changes, fluid retention and mood effects. Thrombosis risk and other medical conditions need assessment. The intrauterine system can cause cramping or spotting and requires correct placement. Discuss side effects early so that treatment and surveillance are not interrupted without a plan.
Monitoring response
Biopsies are generally repeated every 3–6 months. The aim is complete histological response, meaning no cancer or relevant precursor remains in the sampled tissue. Ultrasound improvement and stopping bleeding are insufficient substitutes. The European fertility guideline recommends two complete-response biopsies at least three months apart before pregnancy planning.
Response is usually expected within a defined period, commonly 6–12 months. Persistent disease, progression, recurrence or inability to continue surveillance requires multidisciplinary reconsideration. Conservative treatment should not continue indefinitely simply because surgery is emotionally difficult. The team should explain the threshold for changing course before treatment begins.
Pregnancy planning and later surgery
After confirmed response, early referral to reproductive specialists can help plan conception and avoid unnecessary delay. Assisted reproduction may be appropriate, depending on age, fertility factors and preferences. A response does not guarantee pregnancy or a live birth. If pregnancy is deferred, maintenance progestin treatment and ongoing surveillance may be recommended.
Definitive hysterectomy is generally discussed after childbearing or when conservative treatment fails. Recurrence can occur even after an initial response. Whether ovaries can remain is a separate decision based on age, disease and genetic risk. If hysterectomy is required, options involving stored eggs or embryos and a gestational carrier depend on medical suitability, law, availability and personal wishes.
Practical decision table
| Before treatment | During treatment | After response |
|---|---|---|
| Confirm grade, no invasion and no spread | Attend biopsies and report symptoms | Obtain documented clearance before trying to conceive |
| Review genetics and fertility goals | Discuss toxicity and stopping rules | Coordinate oncology and fertility care |
| Understand surgery remains standard | Reassess nonresponse or progression | Revisit definitive surgery after childbearing |
Questions and take-home messages
Ask: Am I within established selection criteria? How will response be measured? What happens if I do not respond? Who coordinates fertility treatment? It is reasonable to seek psychological support while making these decisions. Preserving fertility is valuable, but the plan must remain anchored to cancer safety.
Related chapters
References and review status
- ESGO/ESHRE/ESGE fertility-sparing guideline, 2023
- ESGO–ESTRO–ESP endometrial carcinoma guideline update, 2025
- ACOG Clinical Consensus: EIN / atypical hyperplasia, 2023
Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy